Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 3/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20856928 | 0.84 | TDP1 (0.38) | ARG1ARG2 | |
| SCHEMBL14697385 | 0.81 | ALOX5 (0.36) | ARG1ARG2 | |
| SCHEMBL8667941 | 0.81 | ALOX5 (0.36) | ARG1ARG2 | |
| Ammonia Solution, Strong SCHEMBL7720467 | 0.81 | CYP1A2 (0.37) | ARG1ARG2 | |
| SCHEMBL16653037 | 0.81 | ALOX5 (0.36) | ARG1ARG2 | |
| SCHEMBL16652985 | 0.81 | ALOX5 (0.36) | ARG1ARG2 | |
| SCHEMBL8411260 | 0.81 | ALOX5 (0.36) | ARG1ARG2 | |
| SCHEMBL15913320 | 0.80 | — | — | |
| SCHEMBL15913342 | 0.78 | — | — | |
| SCHEMBL4820580 | 0.78 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-01-17 | — | — | US | claimed |
| EP-3400231-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | Technion Research & Development Foundation Limited (IL) | 2018-11-14 | — | — | EP | claimed |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2018-10-04 | — | — | US | claimed |
| CN-108350014-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2018-07-31 | — | — | CN | claimed |
| EP-3344641-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | Eloxx Pharmaceuticals Ltd. (IL) | 2018-07-11 | — | — | EP | claimed |
| WO-2017118967-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | WO | claimed |
| WO-2017037719-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2017-03-09 | — | — | WO | claimed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-114957357-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-108350014-B | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-09-30 | — | — | US | disclosed |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-01-26 | — | — | US | disclosed |
| US-20190016746-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2019-01-17 | — | — | US | disclosed |
| US-4038478-A | ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4031304-A | Process for preparing lincomycin derivatives | THE UPJOHN COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4004029-A | BENZAMIDES | THE UPJOHN COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3976667-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
| US-3944562-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | MME 2036/4885ARG1 1664/4885ARG2 1779/4885 |
| US-20190016746-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, GET3 | MME 2683/4885ARG1 1574/4885ARG2 2133/4885 |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | ALPI, MGAM, AASDHPPT | MME 371/4885ARG1 165/4885ARG2 233/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | MME 2036/4885ARG1 1664/4885ARG2 1779/4885 |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | MME 2036/4885ARG1 1664/4885ARG2 1779/4885 |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | MME 2036/4885ARG1 1664/4885ARG2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.